Skip to main content

Advertisement

SpringerLink
Log in

Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Early Breast Cancer Trialists' Collaborative Group. (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717

  2. Baum M et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131–2139

    Article  CAS  Google Scholar 

  3. Ellis M et al. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ERB-1 and/or Erb-2 positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J Clin Oncol 19: 3808–3816

    Article  CAS  Google Scholar 

  4. Osborne CK et al. (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11(Pt 2): 865s–870s

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Assistant Attending Physician on the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Maura Dickler

Authors
  1. Maura Dickler
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Dr Dickler participates in an AstraZeneca Speakers' Bureau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dickler, M. Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?. Nat Rev Clin Oncol 2, 498–499 (2005). https://doi.org/10.1038/ncponc0298

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0298

  • Springer Nature Limited

Search

Navigation